China Resources Boya Bio-pharmaceutical Group Co.,Ltd

SZSE:300294 Stock Report

Market Cap: CN¥14.6b

China Resources Boya Bio-pharmaceutical GroupLtd Future Growth

Future criteria checks 4/6

China Resources Boya Bio-pharmaceutical GroupLtd is forecast to grow earnings and revenue by 44.4% and 13.9% per annum respectively. EPS is expected to grow by 44.5% per annum. Return on equity is forecast to be 8% in 3 years.

Key information

44.4%

Earnings growth rate

44.5%

EPS growth rate

Biotechs earnings growth57.2%
Revenue growth rate13.9%
Future return on equity8.0%
Analyst coverage

Good

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality

Nov 01
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality

A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

Oct 01
A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Sep 12
Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

Jul 25
Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

Jun 12
China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Apr 26
China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

Apr 22
Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

Apr 01
China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

Mar 31
What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

Earnings and Revenue Growth Forecasts

SZSE:300294 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,3056986906896
12/31/20252,0516146215917
12/31/20241,7275107028152
9/30/20241,707186246378N/A
6/30/20242,007228376460N/A
3/31/20242,295219458543N/A
12/31/20232,652237554642N/A
9/30/20232,866478609745N/A
6/30/20232,901479592761N/A
3/31/20232,910499647797N/A
12/31/20222,759432458596N/A
9/30/20222,722439459549N/A
6/30/20222,754426525578N/A
3/31/20222,6813471,1521,208N/A
12/31/20212,6513451,2771,345N/A
9/30/20212,6673601,2811,410N/A
6/30/20212,5862971,3331,474N/A
3/31/20212,528265669808N/A
12/31/20202,513260576719N/A
9/30/20202,664332533622N/A
6/30/20202,755374134228N/A
3/31/20202,867433-5938N/A
12/31/20192,909426-203-115N/A
9/30/20192,867501-369-286N/A
6/30/20192,735491-214-140N/A
3/31/20192,609486-110-34N/A
12/31/20182,388469-7935N/A
9/30/20182,30741921137N/A
6/30/20182,012390N/A115N/A
3/31/20181,732362N/A-3N/A
12/31/20171,390357N/A-24N/A
9/30/20171,132316N/A21N/A
6/30/20171,085324N/A94N/A
3/31/2017994301N/A168N/A
12/31/2016947272N/A199N/A
9/30/2016839227N/A146N/A
6/30/2016720187N/A143N/A
3/31/2016615145N/A149N/A
12/31/2015543152N/A147N/A
9/30/2015498138N/A114N/A
6/30/2015472130N/A95N/A
3/31/2015452130N/A95N/A
12/31/2014438104N/A122N/A
9/30/201436696N/A112N/A
6/30/201432189N/A113N/A
3/31/201427885N/A93N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300294's forecast earnings growth (44.4% per year) is above the savings rate (2.8%).

Earnings vs Market: 300294's earnings (44.4% per year) are forecast to grow faster than the CN market (25% per year).

High Growth Earnings: 300294's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300294's revenue (13.9% per year) is forecast to grow faster than the CN market (13.3% per year).

High Growth Revenue: 300294's revenue (13.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300294's Return on Equity is forecast to be low in 3 years time (8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 09:39
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China Resources Boya Bio-pharmaceutical Group Co.,Ltd is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Fang QuanChina International Capital Corporation Limited
Bing ZhaoChina Renaissance Securities